90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic im
about
Side effects of yttrium-90 radioembolizationFunctional imaging biomarkers for assessing response to treatment in liver and lung metastasesThe role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based reviewDevelopment of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panelLocoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.Colorectal hepatic metastasis: Evolving therapies.Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes.Research reporting standards for radioembolization of hepatic malignancies.Radioembolization for primary and metastatic liver cancer.Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.Anniversary paper: nuclear medicine: fifty years and still countingClinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response?Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.A first report of radioembolization for hepatic metastases from ocular melanoma.State of the art: radiolabeled microspheres treatment for liver malignancies.Intra-arterial therapies for hepatocellular carcinoma: where do we stand?Imaging tumor response following liver-directed intra-arterial therapy.A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.Intra-arterial therapies for metastatic colorectal cancer.Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.Advances in understanding of colorectal liver metastasis and implications for the clinic.(90)Y-glass microspheres for hepatic neoplasia.The state of regional therapy in the management of metastatic colorectal cancer to the liver.Targeted radionuclide therapy.Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres.C-arm computed tomography compared with positron emission tomography/computed tomography for treatment planning before radioembolization.Absorbed dose to lesion and clinical outcome after liver radioembolization with 90Y microspheres: a case report of PET-based dosimetry.Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment.Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments.Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.Resin 90Y microsphere activity measurements for liver brachytherapy.
P2860
Q26821887-788F6E6D-CAFA-4CF7-AC13-47719BB6313CQ26860708-BF5D4A9E-463C-4BEE-AECA-B31C3B722000Q26863629-4C351666-AF18-4EA9-ABDD-831F5FC67524Q27014926-07CACD4B-1006-4F5E-AFE6-2F7F11C53170Q30415022-86BF9604-9F5E-4795-B4A0-C07CA0BFDCEDQ33911553-8BE2E548-1315-4C35-8B11-8B88BF120AFDQ34563356-F8122076-44ED-4D72-993A-DAA6EE2A0901Q34663557-30DE9413-F823-45AB-ABEB-A54EA38FCC0AQ34874473-D5ACF089-B735-4461-B2BF-ED571CCA1E3FQ35094057-D8289DE4-5CFF-4334-A98D-F054389E168AQ35111887-CCBB2EDF-2E69-4978-ACD8-D7642AB2690BQ35564038-2D993A9C-901E-4D76-8DC0-E76E241C5D14Q36352452-EF448651-2736-4DAA-BB58-8C5E221A3B5DQ36482781-B58D8B4C-56E1-4FC4-8B86-16E3E75361DBQ36728823-52E72BAE-4CCD-4B60-B43F-67D844268246Q37131705-74D8A072-CFCD-47DB-B0D6-4A5AF3209DA8Q37170144-F359D67F-A5C9-458C-B124-7BA4599954D6Q37308725-6460AAD6-79BB-4482-9A09-A8268D09A697Q37316201-A108E6E8-146C-4216-9F7B-0A6460BCF40AQ37326857-1ED02A6F-D1E1-49B0-ADD7-40E47F528A03Q37393973-EE1357F1-08F5-4BDF-9B02-C1C24B8BE717Q37693928-C477FFDA-37DA-4267-89CD-C2AE5F12FC2CQ37734300-8C559833-05C7-4D79-B50D-94094A945545Q38117579-D855EBD3-A901-4861-9157-BAD64F144D56Q38169587-C83A58E4-723F-4C7B-9B90-172D2900D2E8Q38179343-8D411B8C-A444-444A-B3A1-3CE105F59AE5Q38206730-41E73BC3-6869-43AA-855F-53D37DF776F1Q38230654-72731A53-C10B-4655-8D43-F58AF7FECBB7Q38465831-8C35F11A-09E1-4E16-B28F-9C6F2ABED5ACQ38664762-1BEA0015-5D79-4B75-814A-F06AAC0895DEQ38781307-D057453D-14EE-4EA4-9F02-39DA3A8EC72FQ38813248-E10EC0C2-36EA-4E02-A045-A0E557FAF708Q38830196-2B87BF1E-6659-4171-8491-C674284F3340Q39456177-2BBFFC4B-2013-4E0A-B4C3-D12A29C4E8BFQ39935458-7C4945A2-A2A8-4A8D-8FDE-3CF1E396F411Q45829453-603CF13D-9D38-4842-B554-EC8DC5E423D2Q47582099-4A963763-58BC-4728-AD03-9572BCFBC9C6Q47677737-6325492C-A049-4610-AFCB-833BC4045F46Q47953062-9A797E2F-F293-4B72-BB32-B59A374EF695Q50950894-E404C02E-30A2-4896-847A-080DC2F81050
P2860
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic im
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
90Y microsphere (TheraSphere) ...... hy and computed tomographic im
@en
90Y microsphere
@nl
type
label
90Y microsphere (TheraSphere) ...... hy and computed tomographic im
@en
90Y microsphere
@nl
prefLabel
90Y microsphere (TheraSphere) ...... hy and computed tomographic im
@en
90Y microsphere
@nl
P2093
P1476
90Y microsphere (TheraSphere) ...... hy and computed tomographic im
@en
P2093
Ching-Yee O Wong
James E Goin
Jean-Francois H Geschwind
Kenneth G Thurston
Mark Van Buskirk
Robert J Lewandowski
P304
P356
10.1097/01.RVI.0000179815.44868.66
P577
2005-12-01T00:00:00Z